Katz Ofrat Beyar, Ben Barak Ayelet, Abrahami Gall, Arad Nira, Burstein Yoav, Dvir Rina, Fischer Salvador, Kapelushnik Joseph, Kaplinsky Haim, Toren Amos, Vilk-Revel Shoshana, Weintraub Michael, Yaniv Isaac, Linn Shai, Futerman Boris, Ben-Arush Myriam Weyl
Department of Pediatric Hematology-OncologyMeyer Children's Hospital, Rambam Health Care Campus affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Isr Med Assoc J. 2011 Mar;13(3):161-5.
Survival in T cell lymphoblastic lymphoma has improved over the past 30 years, largely due to treatment protocols derived from regimens designed for children with acute lymphoblastic leukemia.
To assess the outcome of the NHL-BFM-95 protocol in children and adolescents hospitalized during the period 1999-2006.
We conducted a retrospective multi-institutional, non-randomized study of children and adolescents up to age 21 with T cell lymphoma admitted to pediatric departments in six hospitals in Israel, with regard to prevalence, clinical characteristics, pathological characteristics, prognostic factors, overall survival (OS) and event-free survival (EFS). All patients had a minimal follow-up of one year after diagnosis. The study was based on the NHL-BFM-95 protocol.
At a median follow-up of 4 years (range 1-9 years), OS and EFS for all patients was 86.5% and 83.8%, respectively. OS was 86.7% and 83.3% for patients with stage III and stage IV, respectively, and EFS was 83.3% and 83.3%, respectively. EFS was 62.5% for Arab patients and 89.7% for Jewish patients (P = 0.014). Patients who did not express CD45 antigen showed superior survival (P = 0.028). Five patients (13.5%) relapsed, four of whom died of their disease. Death as a consequence of therapy toxicity was documented in one patient while on the re-induction protocol (protocol IIA).
Our study shows that OS and EFS for all patients was 86.5% and 83.8%, respectively.
在过去30年中，T细胞淋巴母细胞淋巴瘤患者的生存率有所提高，这主要归功于借鉴儿童急性淋巴细胞白血病治疗方案所制定的治疗方案。
评估1999年至2006年期间住院的儿童和青少年采用NHL-BFM-95方案的治疗结果。
我们对以色列6家医院儿科收治的21岁及以下T细胞淋巴瘤儿童和青少年进行了一项回顾性多机构非随机研究，内容包括患病率、临床特征、病理特征、预后因素、总生存率（OS）和无事件生存率（EFS）。所有患者诊断后至少随访1年。该研究基于NHL-BFM-95方案。
中位随访4年（范围1至9年）时，所有患者的OS和EFS分别为86.5%和83.8%。III期和IV期患者的OS分别为86.7%和83.3%，EFS均为83.3%。阿拉伯患者的EFS为62.5%，犹太患者为89.7%（P = 0.014）。未表达CD45抗原的患者生存率更高（P = 0.028）。5例患者（13.5%）复发，其中4例死于疾病。1例患者在再诱导方案（方案IIA）治疗期间因治疗毒性死亡。
我们的研究表明，所有患者的OS和EFS分别为86.5%和83.8%。
